

CENTRACARE Laboratory Services

MEMO

TO: CCLS Clients

FROM: CentraCare Laboratory Services

DATE: 2/11/19

SUBJECT: Estradiol – new interfering substance

Abbott Diagnostics has confirmed that the drug Mifepristone may interfere/cross-react with the current assay, for Estradiol testing, leading to falsely elevated Estradiol levels. The patient impact only applies to patients currently being treated with or recently treated with the drug Mifepristone.

Patients treated with Mifepristone should not be tested using the Abbott method employed at CCLS for Estradiol for up to two weeks based on information available regarding Mifepristone's bioavailability.

Please contact Jerome Schlabsz, Chemistry Technical Specialist Center with any questions at 320-251-2700 Ext. 57325